These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34593018)

  • 41. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    Morishita A; Tadokoro T; Fujihara S; Iwama H; Oura K; Fujita K; Tani J; Takuma K; Nakahara M; Shi T; Haba R; Okano K; Nishiyama A; Ono M; Himoto T; Masaki T
    PLoS One; 2022; 17(2):e0261310. PubMed ID: 35192632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Cami B; De Boe V; Heymans A; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
    Cell Biol Toxicol; 2021 Apr; 37(2):293-311. PubMed ID: 32613381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.
    Christensen CU; Glavind E; Thomsen KL; Kim YO; Heebøll S; Schuppan D; Hamilton-Dutoit S; Würtz Heegaard C; Grønbæk H
    PLoS One; 2018; 13(3):e0192728. PubMed ID: 29522534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
    Dharavath RN; Arora S; Kondepudi KK; Bishnoi M; Chopra K
    Life Sci; 2021 Apr; 271():119191. PubMed ID: 33571514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
    Okishio S; Yamaguchi K; Ishiba H; Tochiki N; Yano K; Takahashi A; Kataoka S; Okuda K; Seko Y; Liu Y; Fujii H; Takahashi D; Ito Y; Kamon J; Umemura A; Moriguchi M; Yasui K; Okanoue T; Itoh Y
    Sci Rep; 2020 Nov; 10(1):19578. PubMed ID: 33177546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
    Gastaldelli A; Sabatini S; Carli F; Gaggini M; Bril F; Belfort-DeAguiar R; Positano V; Barb D; Kadiyala S; Harrison S; Cusi K
    Liver Int; 2021 Nov; 41(11):2659-2670. PubMed ID: 34219361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of saraglitazar on TGF-β-induced smad3 phosphorylation and expression of genes related to liver fibrosis in LX2 cell line.
    Dinarvand N; Afarin R; Shakerian E; Bavarsad SS; Mohammadtaghvaei N
    Mol Biol Rep; 2024 Apr; 51(1):541. PubMed ID: 38642208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats.
    Afarin R; Dinarvand N; Jaberian Asl B; Orak G; Shakerian E; Bineshfar F; Ahangarpour A
    Iran J Basic Med Sci; 2024; 27(2):241-246. PubMed ID: 38234671
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
    Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
    Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.
    Karakan T; Kerem M; Cindoruk M; Engin D; Alper M; Akın O
    Turk J Gastroenterol; 2013; 24(2):134-40. PubMed ID: 23934460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-κB pathway.
    Ma Z; Chu L; Liu H; Li J; Zhang Y; Liu W; Dai J; Yi J; Gao Y
    Int Immunopharmacol; 2016 Sep; 38():377-84. PubMed ID: 27351828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
    van der Veen JN; Lingrell S; Gao X; Quiroga AD; Takawale A; Armstrong EA; Yager JY; Kassiri Z; Lehner R; Vance DE; Jacobs RL
    Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G526-38. PubMed ID: 26797396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
    Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
    J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
    Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
    Nakano Y; Arima T; Tobita Y; Uchiyama M; Shimizu A; Takahashi H
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.